MassDevice Q&A: Accuray president and CEO Euan Thomson

August 16, 2010 by Brad Perriello

Euan Thomson, president and CEO of Accuray Inc., on how his company managed to fare well despite the capital expenditure market's downturn, its distribution and R&D deal with Siemens and why healthcare reform could have a big upside for Accuray.

MassDevice Q&A: Accuray president and CEO Euan Thomson

Accuray Inc. (NSDQ:ARAY) has a tough row to hoe: Cultivate a market that crosses medical specialty lines for a product that costs millions. The Sunnyvale, Calif.-based company's CyberKnife system is a pioneering device in radiosurgery, using precisely targeted, massive doses of X-ray radiation to non-invasively destroy tumors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

Battelle engineering manager Melissa Masters tells MassDevice.com how insights ranging from national security to aeronautics can inform the creation of disruptive new medical devices.

The special sauce in contract research organization Ora Inc.'s recipe for ophthalmology trials is the eye care practice its founder started 30 years ago.

Animal rights advocacy group PETA holds a tiny stake in several medtech companies, taking frequent advantage of its shareholder rights to push changes in the way device makers experiment on animals.

AliveCor's interim-ish CEO Euan Thomson talks about the data-driven future, why he jumped ship at Accuray and how to navigate the intersection between the tempered medical device world and the wanton nimbleness of Silicon Valley.

Medtronic executive Dr. Stephen Oesterle thinks Google will be a force to be reckoned with in the medical technology space in coming years.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp